These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 35756634)

  • 1. Role of Adenoviruses in Cancer Therapy.
    Tseha ST
    Front Oncol; 2022; 12():772659. PubMed ID: 35756634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
    BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.
    Chen GX; Zhang S; He XH; Liu SY; Ma C; Zou XP
    Onco Targets Ther; 2014; 7():1901-9. PubMed ID: 25364261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses.
    Schierer S; Hesse A; Müller I; Kämpgen E; Curiel DT; Schuler G; Steinkasserer A; Nettelbeck DM
    Int J Cancer; 2008 Jan; 122(1):219-29. PubMed ID: 17764070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species D Adenoviruses as Oncolytic Viral Vectors.
    Bullard BL; Corder BN; Weaver EA
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33291224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.
    Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD
    J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.
    Xu W; Yang Y; Hu Z; Head M; Mangold KA; Sullivan M; Wang E; Saha P; Gulukota K; Helseth DL; Guise T; Prabhkar BS; Kaul K; Schreiber H; Seth P
    Hum Gene Ther; 2020 Aug; 31(15-16):863-880. PubMed ID: 32394753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
    Wildner O; Morris JC
    Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy.
    Farzad L; Cerullo V; Yagyu S; Bertin T; Hemminki A; Rooney C; Lee B; Suzuki M
    Mol Ther Oncolytics; 2014; 1():14008. PubMed ID: 27119096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.
    Zhang L; Hedjran F; Larson C; Perez GL; Reid T
    Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in oncolytic adenovirus therapies for cancer.
    Rosewell Shaw A; Suzuki M
    Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.
    Zhang WW; Li L; Li D; Liu J; Li X; Li W; Xu X; Zhang MJ; Chandler LA; Lin H; Hu A; Xu W; Lam DM
    Hum Gene Ther; 2018 Feb; 29(2):160-179. PubMed ID: 29338444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development.
    Luo S; Zhang P; Ma X; Wang Q; Lu J; Liu B; Zhao W; Allain JP; Li C; Li T
    Virus Res; 2019 Jul; 268():1-10. PubMed ID: 31108113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in research on oncolytic adenoviruses in tumor therapy].
    Zhou XL; Tang WR
    Bing Du Xue Bao; 2014 May; 30(3):318-24. PubMed ID: 25118389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a novel oncolytic adenoviral vector and its biological characteristics.
    Zhang M; Zhang X; Han Z; Chen X; Yang L; Sheng Y; Wen J
    Oncol Rep; 2013 Feb; 29(2):798-804. PubMed ID: 23165979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy.
    Cherry T; Longo SL; Tovar-Spinoza Z; Post DE
    Gene Ther; 2010 Dec; 17(12):1430-41. PubMed ID: 20664541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
    Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
    J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines.
    Weaver EA; Nehete PN; Buchl SS; Senac JS; Palmer D; Ng P; Sastry KJ; Barry MA
    PLoS One; 2009; 4(3):e5059. PubMed ID: 19333387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.